regeneus to fast-track human cells, page-6

Analysis

Proactive Investors believes that the new Japanese laws will allow Regeneus to gain a foothold in the regenerative medicine and cell technology sector.

The new laws provide the company with a well-defined pathway to fast-track the clinical trial and potential approval of CryoShot®, which will be a true off-the-shelf product.

Japanese approval will also open up access to the osteoarthritis market there, which given the country’s ageing population is likely to be a comparatively large one.

Osteoarthritis, which was incurable, usually resulted in the need for a hip replacement so there is a real treatment gap and need.

Regeneus is already earning revenues with fast growth potential. This demonstrates how Regeneus is different - very product-focused, developing products and servicing markets with a clear need that generates revenues now from stem cell-related technology products.

Regeneus is product driven first and foremost. It also sells two products, AdiCell and CryoShot, to treat similar musculoskeletal conditions.

While still small in comparison, Regeneus can look to, and beyond Mesoblast Ltd. (ASX:MSB; OTC:MBLTY), with its market capitalisation of $1.9 billion, as an example of where its regenerative medicine ambitions can take it. At $0.51 share price, Proactive Investors can see further growth in the short and medium terms in terms of valuation growth.

http://www.proactiveinvestors.com.au/companies/news/50506/regeneus-to-fast-track-human-stem-cell-osteoarthritis-therapies-in-japan-50506.html